European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

An integrated interdisciplinary approach to animal-free chemical and nanomaterial safety assessment

Descrizione del progetto

Prodotti chimici più sicuri senza test sugli animali

Le sostanze chimiche e i nanomateriali fabbricati potenzialmente nocivi per gli esseri umani vengono testati sugli animali. Nonostante i notevoli miglioramenti in questo settore, manca ancora una piattaforma integrata di valutazione del rischio. Il progetto in3, finanziato dal programma azioni Marie Skłodowska-Curie, intende realizzare una valutazione della sicurezza delle sostanze chimiche e dei nanomateriali fabbricati che non ricorra ai test sugli animali, combinando test umani in vitro con metodi computazionali. L’attenzione si concentrerà sulla moltiplicazione di cellule staminali pluripotenti indotte e sul loro invio a laboratori partner in tutta Europa. Queste cellule hanno la capacità di trasformarsi in pelle, nervi, muscoli o praticamente in qualsiasi altro tipo di cellula rilevante per gli organi o i tessuti bersaglio in cui si verifica l’esposizione ai nanomateriali fabbricati. Di conseguenza possono essere utilizzate nella ricerca su questi nanomateriali, eliminando la necessità di test sugli animali.

Obiettivo

All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The use of whole animal studies for the prediction of adverse effects in man, is problematic due to species dependent effects, high costs and a large burden to animals in terms of numbers and suffering. While there have been major improvements in human in vitro and in silico techniques, there is still a lack of an integrated risk assessment platform. The in3 proposal aims to significantly further the development of animal-free chemical and nanomaterial (NM) safety evaluation by creating a scientific and training program aimed at integrating human in vitro testing with computational approaches. The project will focus on human induced pluripotent stem cells (hiPSC) derived tissues, including liver, kidney, brain, lung and vasculature and to utilise mechanistic toxicology, quantitative adverse outcome pathways, biokinetics, cheminformatics and modelling approaches to derive testable prediction models. hiPSC present the major advantages provide non-cancerous derived tissues with identical genetic backgrounds. All Early Stage Researchers (ESRs) will work towards the same goal, utilising the same chemicals, donor cells, assays and software packages. All data will be centrally housed in standardised formats, appropriately annotated and linked with protocols and material information. While ESRs will hone their skills in their own field of expertise, they will also collaborate to create an in depth safety evaluation testing platform for the chosen test compounds. By interaction, problem solving, training and secondments over the three years, they will acquire a unique set of interdisciplinary skills for chemical and NM safety assessment. The project aims to accelerate the realisation of animal-free safety assessment and to graduate 15 PhD students with the ideal skill sets to carry out the strategy designed in in3 in the near future.

Coordinatore

STICHTING VU
Contribution nette de l'UE
€ 510 748,56
Indirizzo
DE BOELELAAN 1105
1081 HV Amsterdam
Paesi Bassi

Mostra sulla mappa

Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 510 748,56

Partecipanti (13)

Partner (5)